Skip to main content
letter
. 2021 May 18;14:17562864211016641. doi: 10.1177/17562864211016641

Table 1.

Patient characteristics.

Patient no. Sex Age (years) First diagnosis Diagnosis EDSS Last OCR/RTX infusion Start of OCR/RTX treatment PCR test Antibody test SARS-CoV-2 IgG anti-Nucleocapsid SARS-CoV-2 IgG anti-Spike protein Symptoms Management Previous DMT (sequence)
1 F 37 2018 RRMS 1.5 10 July 2020 January 2019 20 October 2020 26 November 2020 Negative Negative Bilateral pneumonia In-patient treatment None
2 F 39 2009 RRMS 4 8 July 2020 May 2018 17 October 2020 09 December 2020 Negative Negative Pneumonia Out-patient treatment Interferon beta 1a, Natalizumab, Interferon beta 1b, Natalizumab, Glatirameracetate, Rituximab
3 F 55 2003 RRMS 3 12 June 2020 April 2018 27 September 2020 10 February 2021 Negative Negative Pneumonia Out-patient treatment Interferon beta 1a, Interferon beta 1b, Glatirameracetate, Natalizumab
4 F 53 2004 RRMS 4 4 June 2020 September 2018 23 October 2020 8 February 2021 Negative Negative Sepsis In-patient treatment Interferon beta 1a, Glatirameracetate, Natalizumab
5a F 44 2017 NMOSD 3 3 July 2020 June 2017 3 December 2020 27 January 2021 Negative Negative Bilateral pneumonia In-patient treatment Interferon beta 1a, Fingolimod, Daclizumab
6 M 47 2020 RRMS 1 14 August 2020 July 2020 30 December2020 17 February 2021 Negative Negative Pneumonia Out-patient treatment None
7 M 53 2014 PPMS 2.5 3 September 19 March 2019 31 March 2020 23 December 2020 Negative Positive Sepsis In-patient treatment None
8 F 69 2004 SPMS 4.5 7 February 2020 August 2017 7 December 2020 10 February 2021 Positive Positive Pneumonia Out-patient treatment Interferon beta 1b
a

Patient 5 has first been diagnosed and treated with an RRMS diagnosis and was classified as NMOSD in 2017.

DMT, disease modifying treatment; EDSS, expanded disability status scale; NMOSD, neuromyelitis optica spectrum disorder; OCR, ocrelizumab; PPMS, primary progressive multiple sclerosis; RTX, rituximab; SARS-CoV-2, severe acute respiratory syndrome corona virus 2; RRMS, relapsing remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.